CN111743812A - Vaginal repair nutrient solution and preparation method thereof - Google Patents

Vaginal repair nutrient solution and preparation method thereof Download PDF

Info

Publication number
CN111743812A
CN111743812A CN202010687327.6A CN202010687327A CN111743812A CN 111743812 A CN111743812 A CN 111743812A CN 202010687327 A CN202010687327 A CN 202010687327A CN 111743812 A CN111743812 A CN 111743812A
Authority
CN
China
Prior art keywords
nutrient solution
skin
collagen
vaginal
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010687327.6A
Other languages
Chinese (zh)
Inventor
蔡文涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi'an Xuanyu Zijin Pharmaceutical Co ltd
Original Assignee
Xi'an Xuanyu Zijin Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xi'an Xuanyu Zijin Pharmaceutical Co ltd filed Critical Xi'an Xuanyu Zijin Pharmaceutical Co ltd
Priority to CN202010687327.6A priority Critical patent/CN111743812A/en
Publication of CN111743812A publication Critical patent/CN111743812A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a vaginal repairing nutrient solution and a preparation method thereof, wherein each kilogram of the nutrient solution contains 1.5 g of diguanosine tetraphosphate, 1.5 g of adenosine triphosphate, AFGF20 g, BFGF 20 g, 50 g of amino acid, 5 g of medical betaine, 10 g of recombinant human collagen, 1 g of benzalkonium bromide, 200 g of glycerol, 0.3 g of borneol, 0.5 g of ethylparaben and the balance of purified water.

Description

Vaginal repair nutrient solution and preparation method thereof
Technical Field
The invention relates to the technical field of health care cosmeceutics, in particular to a vaginal repair nutrient solution and a preparation method thereof.
Background
Nowadays, gynecological diseases always afflict most women, and the repair and nursing of female vagina are more and more important, which can effectively reduce vaginal injury and infection, but the existing nursing liquid has single function and poor effect, can not well play the roles of sterilization, disinfection and cell repair, contains various chemical components which are irritant to skin, and is very easy to cause infection. Therefore, the natural and healthy female vaginal cell repair nursing liquid which can effectively repair the damaged vaginal mucosa, improve vaginal relaxation, recover vaginal tightening state, adjust vaginal flora balance and inhibit harmful flora breeding is urgently needed in the market.
Disclosure of Invention
Aiming at the technical defects, the invention aims to provide a vaginal repair nutrient solution and a preparation method thereof.
In order to solve the technical problems, the invention adopts the following technical scheme:
the invention provides a vaginal repair nutrient solution, which is characterized in that each kilogram of nutrient solution contains 1.5 g of diguanosine tetraphosphate, 1.5 g of adenosine triphosphate, AFGF20 g, BFGF 20 g, 50 g of amino acid, 5 g of medical betaine, 10 g of recombinant human collagen, 1 g of benzalkonium bromide, 200 g of glycerol, 0.3 g of borneol, 0.5 g of ethylparaben and the balance of purified water.
The invention also provides a preparation method of the nutrient solution, which is characterized in that diguanosine tetraphosphate, adenosine triphosphate, AFGF, BFGF, amino acid, medical betaine, recombinant human collagen, benzalkonium bromide, glycerol, borneol and ethylparaben are sequentially added into a volumetric flask to be stirred and dissolved, then water is added to the volumetric flask to be constant in volume of 1L, and the volumetric flask is filled after standing for 24 hours.
The using method comprises the following steps: injecting 5 ml of solution into a special administration device, pushing the solution into a vagina, taking the solution out for 4-6 hours, wherein the solution is taken out once a day, 7 days is a period, and the solution is continuously used every three to five days; the menstrual period was avoided, and the product was administered three days after the end of menstruation.
The invention has the beneficial effects that: rapidly providing required nutrients for the vagina, muscle layers and elastic fiber layers of the vagina; the fractured fibrous layer and the damaged muscle layer can be quickly repaired, and the elasticity of female vaginal tissues can be recovered; is rich in sexual nerve repair factors and can effectively improve the sensitivity.
The following further explains the beneficial effects of the present invention in combination with the efficacy of the main ingredients of the present invention:
diguanosine tetraphosphate is mainly used as a functional raw material in the cosmetic industry at present, and mainly has the following functions: firstly, supplying energy: the substance can be rapidly converted into ATP after entering human body, instantly supplement energy to skin cells, and awaken cells which are dormant due to aging or environmental factors such as heat, UV rays, chemical pollution and the like. In addition, the beet root powder contains red vitamin B12 and high-quality iron, and is the best natural nutriment for women and vegetable consumers to enrich the blood. Secondly, activating cells: the substance can activate various physiological activities and metabolism of cells after entering human body, improve the synthesis capacity of cells to various proteins, such as endoplasmic reticulum aggregatory protein, keratin, collagen, fibronectin, heat shock protein, etc., and improve the self-repairing and supplementing capacity. Meanwhile, the composition can promote the division and proliferation of dermal fibroblasts, increase collagen fibers, reticular fibers and elastic fibers, regulate the content and activity of collagenase, hyaluronic acid, chondroitin sulfate and heparin in the matrix, maintain the water content in dermal connective tissues of the skin, enable the connective tissues to be in a loose state, prevent collagen from being changed from a dissolved state to an undissolved state, prevent wrinkles from being generated, and effectively repair the formed wrinkles. Thirdly, DNA protection: the substance can effectively protect the three-dimensional spiral structure of the DNA from being damaged by environmental factors such as ultraviolet rays and the like.
Adenosine triphosphate, ATP, is a high-energy phosphate compound, and in cells, the adenosine triphosphate and ADP can be interconverted to realize energy storage and energy release, so that energy supply of various vital activities of the cells is ensured.
AFGF, a multifunctional potent cytokine, plays an important role in promoting fibroblast metabolism and collagen formation. AFGF can promote the growth and the propagation of skin tissues, and can regulate and control the division, the propagation, the growth and the differentiation of skin epithelium, endothelium and stromal cells by combining with a cell surface specific receptor, promote the cell metabolism and enhance the oxidation effect; can promote the rapid growth and reproduction of cells related to skin injury, and regulate the synthesis, secretion and decomposition of intercellular matrix; can promote the regeneration of stratum corneum cells, accelerate the repair of stratum corneum and matrix layers of the skin and promote the growth of skin cells of a human body; can enhance the synthesis and cell metabolism of skin cells, delay skin cell aging, promote repair and growth of epidermal cells, and make skin smooth and plump.
BFGF, a basic fibroblast growth factor, is a polypeptide that transmits developmental signals that promote mesodermal and neuroectodermal cell division. Has strong angiogenesis effect. In vitro, it can stimulate cell proliferation and migration, induce plasminogen activator and collagenase activity, and is a cell mitogen with high affinity to heparin.
Amino acids, which are metabolized in the human body to exert the following effects: firstly, synthesizing tissue protein; ② changing into ammonia-containing substances such as acid, hormone, antibody, creatine and the like; ③ to carbohydrate and fat; and oxidizing the carbon dioxide, the water and the urea to generate energy.
Betaine is used as humectant in cosmetics, and can easily interact with water to produce moisture-keeping effect. Betaine has excellent moisturizing ability and is not sticky when used. It can make face smoother after application, and can be used for relieving skin allergy in combination with other components, and is ideal sedative humectant. Can balance cell osmotic pressure, and can help cells to restore to balance and moisture state when skin encounters adverse environment, cell osmotic pressure is unbalanced, and cells lose water.
Recombinant human collagen, which is one of the most abundant proteins in human body. Collagen hydrolysates have been shown to have significant biological activities such as antioxidant properties, antihypertensive activity, lipid-lowering activity, and repair of damaged skin properties. Collagen has a dual role in the skin: building blocks formed of elastin and collagen are provided, acting as ligands or binding to fibroblast receptors stimulating the synthesis of hyaluronic acid. Type I collagen and type iii collagen are closely related to the process and quality of skin injury repair. Normal fetal skin type III collagen accounts for 60%, and with growth and development, type III collagen continuously decreases, and type I collagen continuously increases. Adult skin collagen consists of type I80% and type III 20%. The mechanism of scar-free healing in the fetus is due to the strong ability of the fetus to synthesize type iii collagen. The basic structure of the recombinant human collagen is the same as that of a human body, and meanwhile, the basic structure is optimized on the basis, so that the hydrophilicity and the activity of the collagen are improved. Contains a large amount of hydrophilic genes, has good film forming property and can keep the moisture of the skin stratum corneum. Meanwhile, the tropism guiding function of the skin healing promoting agent can guide epithelial cells to rapidly enter the damaged part, effectively improve the skin regeneration speed, shorten the wound healing time and further recover the skin barrier function.
Detailed Description
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
Example 1
A vagina repair nutrient solution contains 1.5 g of diguanosine tetraphosphate, 1.5 g of adenosine triphosphate, AFGF20 g, BFGF 20 g, 50 g of amino acid, 5 g of medical betaine, 10 g of recombinant human collagen, 1 g of benzalkonium bromide, 200 g of glycerol, 0.3 g of borneol, 0.5 g of ethylparaben and the balance of purified water.
The preparation method comprises the following steps: sequentially adding diguanosine tetraphosphate, adenosine triphosphate, AFGF, BFGF, amino acid, medical betaine, recombinant human collagen, benzalkonium bromide, glycerol, borneol and ethylparaben into a volumetric flask, stirring for dissolving, adding water to a constant volume of 1L, standing for 24 hours, and filling.
Experimental data:
1. the experimental population is as follows: 100 persons without lochia in the full moon after delivery are selected as test objects.
2. The test method comprises the following steps: combined with the postpartum rehabilitation center of a hospital, 100 women with outstanding vaginal relaxation and urine leakage problems are screened out, and the product is continuously used for three months.
3. And (3) data statistics: after the product is used for three months, the effective rate of the product is 98 percent, and the ineffective rate is 2 percent. 35 patients with vaginal relaxation and leakage of urine; the product use satisfaction rate is 92%.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims (2)

1. The vagina repair nutrient solution is characterized in that each kilogram of the nutrient solution contains 1.5 g of diguanosine tetraphosphate, 1.5 g of adenosine triphosphate, 1.5 g of AFGF20 g of BFGF 20 g of amino acid, 5 g of medical betaine, 10 g of recombinant human collagen, 1 g of benzalkonium bromide, 200 g of glycerol, 0.3 g of borneol, 0.5 g of ethylparaben and the balance of purified water.
2. The method for preparing the nutrient solution as claimed in claim 1, wherein diguanosine tetraphosphate, adenosine triphosphate, AFGF, BFGF, amino acids, medical betaine, recombinant human collagen, benzalkonium bromide, glycerol, borneol and ethylparaben are sequentially added into a volumetric flask to be stirred and dissolved, then water is added to the volumetric flask to be constant volume of 1L, and the volumetric flask is filled after standing for 24 hours.
CN202010687327.6A 2020-07-16 2020-07-16 Vaginal repair nutrient solution and preparation method thereof Pending CN111743812A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010687327.6A CN111743812A (en) 2020-07-16 2020-07-16 Vaginal repair nutrient solution and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010687327.6A CN111743812A (en) 2020-07-16 2020-07-16 Vaginal repair nutrient solution and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111743812A true CN111743812A (en) 2020-10-09

Family

ID=72711205

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010687327.6A Pending CN111743812A (en) 2020-07-16 2020-07-16 Vaginal repair nutrient solution and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111743812A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113081880A (en) * 2021-04-24 2021-07-09 杭州移联网络科技有限公司 Female vaginal nutrient solution formula and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104667335A (en) * 2015-01-27 2015-06-03 山西锦波生物医药股份有限公司 Recombinant human-derived collagen product for skin barrier function or haemorrhoids and preparation method
CN105168040A (en) * 2015-08-18 2015-12-23 广东轻工职业技术学院 Composite anti-ageing skin-care composition and manufacturing method
CN105169374A (en) * 2015-10-23 2015-12-23 东莞市达庆医疗器械有限公司 Recombinant human collagen gel and preparation method thereof
CN105193671A (en) * 2015-10-29 2015-12-30 苏建华 Nourishing skin care lotion and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104667335A (en) * 2015-01-27 2015-06-03 山西锦波生物医药股份有限公司 Recombinant human-derived collagen product for skin barrier function or haemorrhoids and preparation method
CN105168040A (en) * 2015-08-18 2015-12-23 广东轻工职业技术学院 Composite anti-ageing skin-care composition and manufacturing method
CN105169374A (en) * 2015-10-23 2015-12-23 东莞市达庆医疗器械有限公司 Recombinant human collagen gel and preparation method thereof
CN105193671A (en) * 2015-10-29 2015-12-30 苏建华 Nourishing skin care lotion and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐威 等: "《药学细胞生物学》", 31 August 2015, 中国医药科技出版 *
汪文杰 等: "《血管瘤和脉管畸形诊断与治疗》", 31 July 2012, 人民军医出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113081880A (en) * 2021-04-24 2021-07-09 杭州移联网络科技有限公司 Female vaginal nutrient solution formula and preparation method thereof

Similar Documents

Publication Publication Date Title
KR101678621B1 (en) Composition comprising spicules for skin care
CN101791283B (en) Cosmetic capable of eliminating striae gravidarum and scars
CN108210887A (en) A kind of Medical cold application and preparation method thereof
CN102085172B (en) Skin care cosmetic taking American wild yam extract as main component and preparation method thereof
CN111110623A (en) Self-repairing small needle nutrient solution formula
CN104814901B (en) One kind prevention striae of pregnancy gel and preparation method thereof
CN106074213A (en) Hyaluronic acid sodium gel for water optoinjection and its preparation method and application
CN104921983A (en) Medical biological repairing dressing for pregnant woman striae gravidarum and preparation method thereof
CN108686255A (en) It is a kind of to prevent the biological dressing and preparation method thereof that scar is formed
KR102452905B1 (en) the method for skin improvement cosmetic composition containing natural spicule and polydioxanone and the cosmetic composition thereof
CN108743921A (en) It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed
CN103860449A (en) Skin care product with effect of removing stretch marks and preparation method thereof
CN113521258A (en) Tissue injection for improving aging
KR20180134468A (en) Cosmetic compositions comprising spicule, marine collagen and deep ocean water and their preparation
CN111743812A (en) Vaginal repair nutrient solution and preparation method thereof
KR101859499B1 (en) Cosmetic composition biomimetically designed from extracellular matrix for promoting the stemness of adipose-derived stem cell
CN106344435A (en) Skin protection cream capable of eliminating striae gravidarum
CN113332193A (en) Composition and massage cream for preventing stretch marks
KR101305274B1 (en) Composition for improving collagen synthesis
KR101218898B1 (en) Composition for improving collagen synthesis
WO2007046353A1 (en) Fibroblast activator, method for activation of fibroblast, collagen synthesis promoter, method for promotion of collagen synthesis, skin aging-preventing agent, and method for prevention of aging of the skin
KR20100082750A (en) Functional cosmetic composition foaming carbon dioxide
CN112754981A (en) Collagen regeneration promoting preparation and preparation method and application thereof
CN105267949A (en) Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof
CN101297705A (en) Compound Tibet sheep placenta capsule for removing wrinkle and resisting aging

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201009